Patents Assigned to Cocensys, Inc.
-
Patent number: 6534525Abstract: Novel 2-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 2-substituted piperidine analogs as selectively active antagonist of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headaches, chronics pain, glaucoma, CMV retinitis, psychosis, urinary incontinence, opioid tolerance or withdrawal, or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.Type: GrantFiled: June 21, 2000Date of Patent: March 18, 2003Assignees: Warner-Lambert & Company, Cocensys, Inc.Inventors: Christopher F. Bigge, John F. W. Keana, Sui Xiong Cai, Eckard Weber, Richard Woodward, Nancy C. Lan, Anthony P. Guzikowski
-
Publication number: 20020061886Abstract: This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by Formula I: 1Type: ApplicationFiled: December 6, 2001Publication date: May 23, 2002Applicant: CoCensys, Inc.Inventors: Yan Wang, Sui Xiong Cai, John FW Keana
-
Patent number: 6335354Abstract: This invention relates to aminopyridines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1-R8, X and m are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.Type: GrantFiled: March 29, 2001Date of Patent: January 1, 2002Assignee: CoCensys Inc.Inventor: Derk J. Hogenkamp
-
Publication number: 20010044428Abstract: This invention relates to aminopyridines of Formula I: 1Type: ApplicationFiled: March 29, 2001Publication date: November 22, 2001Applicant: CoCensys, Inc.Inventor: Derk J. Hogenkamp
-
Patent number: 6277838Abstract: Methods, compositions, and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.Type: GrantFiled: April 11, 2000Date of Patent: August 21, 2001Assignee: Cocensys, Inc.Inventors: Ravindra B. Upasani, Haiji Xia, Derk Hogenkamp
-
Patent number: 6251903Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.Type: GrantFiled: September 13, 2000Date of Patent: June 26, 2001Assignees: Cocensys, Inc., State of Oregon, Acting by and through the Oregon State Board of Higher Education, Acting for and on behalf of the Oregon Health Sciences University and the University of Oregon, The Regents of the University of CaliforniaInventors: Sui Xiong Cai, Eckard Weber, John F. W. Keana, Sunil Kher
-
Patent number: 6218404Abstract: The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neuro-degenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.Type: GrantFiled: September 16, 1998Date of Patent: April 17, 2001Assignees: Warner-Lambert Co., Cocensys, Inc.Inventors: Christopher F. Bigge, Gian Luca Araldi, Sui Xiong Cai, Anthony P. Guzikowski, Donald Lamunyon, Nancy F. Lan, Zhang-Lin Zhou, John F. W. Keana
-
Patent number: 6147075Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.Type: GrantFiled: August 18, 1999Date of Patent: November 14, 2000Assignees: CoCensys, Inc., State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University and the University of Oregon, Eugene Oregon, The Regents of the University of CaliforniaInventors: Sui Xiong Cai, Eckard Weber, John F. W. Keana, Sunil Kher
-
Patent number: 6143736Abstract: Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.Type: GrantFiled: July 8, 1999Date of Patent: November 7, 2000Assignee: CoCensys, Inc.Inventors: Ravindra B. Upasani, Haiji Xia, Derk Hogenkamp
-
Patent number: 6124317Abstract: Novel 2-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 2-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartatc (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, amioglycoside antibiotics-induced hearing loss, migraine headaches, chronic pain, glaucoma, CMV retinitis, psychosis, urinary incontinence, opioid tolerance or withdrawal, or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.Type: GrantFiled: November 18, 1998Date of Patent: September 26, 2000Assignees: Warner-Lambert Company, Cocensys, Inc.Inventors: Christopher F. Bigge, John F. W. Keana, Sui Xiong Cai, Eckard Weber, Richard Woodward, Nancy C. Lan, Anthony P. Guzikowski
-
Patent number: 5977107Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.Type: GrantFiled: January 31, 1997Date of Patent: November 2, 1999Assignees: Cocensys, Inc., State of Oregon, Acting by and Through the Oregon State Board of Higher Education, acting for and on Behalf of the Oregon Health Sciences University and the University of Oregon, Eugene Oregon, The Regents of the University of CaliforniaInventors: Sui Xiong Cai, Eckard Weber, John F. W. Keana, Sunil Kher
-
Patent number: 5939545Abstract: Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.Type: GrantFiled: July 2, 1997Date of Patent: August 17, 1999Assignee: CoCensys, Inc.Inventors: Ravindra B. Upasani, Haiji Xia, Derk Hogenkamp
-
Patent number: 5925630Abstract: The invention relates to 3.alpha.-hydroxy, 17-(un)substituted derivatives of the androstane series and 3.alpha.-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified site on the GRC, thereby modulating brain excitability in a manner that will alleviate stress, anxiety, insomnia, mood disorders that are amenable to GRC-active agents (such as depression) and seizure activity. The steroid derivatives of this invention are those having the general structural Formula: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are further defined herein and the dotted lines are single or double bonds. The structure includes androstanes, pregnanes (R.sub.4 =methyl), 19-norandrostanes, and norpregnanes (R.sub.4 =H).Type: GrantFiled: June 6, 1996Date of Patent: July 20, 1999Assignee: CoCensys, Inc.Inventors: Ravindra B. Upasani, David B. Fick, Derk J. Hogenkamp, Nancy C. Lan
-
Patent number: 5891871Abstract: The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, CMV retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition enhancers.Type: GrantFiled: March 20, 1997Date of Patent: April 6, 1999Assignee: CoCensys, Inc.Inventors: Haiji Xia, Sui Xiong Cai, George Field, Nancy C. Lan, Yan Wang
-
Patent number: 5883229Abstract: Mammalian genes coding for bcl-y are disclosed. Bcl-y is involved in mediating cell death or survival.Type: GrantFiled: November 25, 1997Date of Patent: March 16, 1999Assignee: CoCensys, Inc.Inventor: John Guastella
-
Patent number: 5863916Abstract: Disclosed are compounds of the formula: ##STR1## or pharmaceutically acceptable salts thereof; wherein n is zero or 1; R.sup.4, R.sup.5, R.sup.6 are independently hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, cycloalkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy, or haloalkoxy; and R.sup.c and R.sup.d are defined in the specification. These compounds have high binding to the glycine site of the NMDA receptor. Also disclosed are methods of treating pathophysiologic conditions associated with neuronal degeneration, convulsions, anxiety, chronic pain, pyschosis, opiate tolerance, and inducing anesthesia.Type: GrantFiled: February 4, 1997Date of Patent: January 26, 1999Assignees: State of Oregon, Acting by and Through the Oregon State Board of Higher-Education, Acting for and on Behalf of the Oregon Health Sciences University and The University of Oregon, The Regents of the University of California, Cocensys, Inc.Inventors: Sui Xiong Cai, John F. W. Keana, Eckard Weber
-
Patent number: 5801183Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia, and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment or prevention a substituted or unsubstituted pyridine and pyridine (N-oxide) analogs of 4-hydroxydihydroquinolones, tetrahydroquinoline-trione-oximes and quinoxalones, tautomers and pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.Type: GrantFiled: June 6, 1995Date of Patent: September 1, 1998Assignees: State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University and the University of Oregon, Cocensys, Inc.Inventors: John F. W. Keana, Sui Xiong Cai, Zhang-Lin Zhou, James M. Navratil
-
Patent number: 5789201Abstract: Mammalian genes coding for bcl-y are disclosed. Bcl-y is involved in mediating cell death or survival.Type: GrantFiled: February 11, 1997Date of Patent: August 4, 1998Assignee: CoCensys, Inc.Inventor: John Guastella
-
Patent number: 5567830Abstract: A method for the preparation of an acetylenic alcohol by reaction of 1,2-dibromoethylene with an alkyl, aryl an heteroaryl lithium in an inert solvent, followed by reaction with a carbonyl-containing compound to give an acetylenic alcohol is disclosed.Type: GrantFiled: February 14, 1994Date of Patent: October 22, 1996Assignee: Cocensys, Inc.Inventor: Ravindra B. Upasani
-
Patent number: 5449795Abstract: A method for the preparation of a steroidal allylic tertiary alcohol is disclosed which involves the deprotonation of a sulfoxide with a strong base which is capable of deprotonating the methine proton which is .alpha. to the sulfoxide, in an inert solvent to give the anion; reaction of the anion with a steroidal spiro-2'-oxirane to give a steroidal .gamma.-hydroxysulfoxide; and thermolysis in the presence of a base other than calcium carbonate to give the steroidal allylic tertiary alcohol.Type: GrantFiled: February 14, 1994Date of Patent: September 12, 1995Assignee: CoCensys, Inc.Inventor: Derk J. Hogenkamp